Clinical Trial Update: Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects- [Phase 1]

View source ↗

Summary

Phase I repeat-dose study of SB-480848 (darapladib) in healthy Japanese male subjects has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis

Drugs mentioned

• Darapladib (darapladib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Atherosclerosis | Phase 1 | Status: COMPLETED